Deciphera Pharmaceuticals, Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2023. The company announced preliminary total revenue of approximately $47 million for the fourth quarter ended December 31, 2023 and approximately $162 million for the full year ended December 31, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.65 USD | +3.31% | -0.14% | -9.18% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.18% | 1.2B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- DCPH Stock
- News Deciphera Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023